News

With an expected capacity up to 50 million units, the new Lantus SoloSTAR investment will allow Sanofi-Aventis to better meet the growth demand of the Chinese market and

Actelion has reported net revenues of CHF405.6 million for the first quarter of 2009, an increase of 26%, compared to CHF321.6 million for the first quarter of 2008.

Net sales for the first quarter of 2009 were $2.01 billion, which included sales from divested businesses of $4 million, as compared to net sales of $2.05 billion

Under the terms of the agreement, Galapagos’s service division BioFocus DPI will perform biology, medicinal chemistry and ADME/PK services for an Opsona drug discovery program. Opsona will make

Pfizer and Medivation, a biopharmaceutical company, have initiated a 12-month, Phase III clinical trial of the investigational drug Dimebon. The study, known as Concert, is designed to evaluate

Gilead Sciences, a biopharmaceutical company, has started enrolling patients in a Phase II clinical trial of its investigational integrase-based, single-tablet, once-daily regimen of elvitegravir, GS 9350 and Truvada

Icagen, a biopharmaceutical company, has presented positive results from its Phase I program for ICA-105665, the company’s lead drug candidate for the treatment of epilepsy and neuropathic pain.

Dendreon, a biotechnology company, has reported positive data from its Protect or P-11 Phase III study suggesting that Provenge induces long-term memory immune responses that are durable and

Revenues for the fourth quarter of 2008 were $843,000, an increase of 231% from the $255,000 reported for the fourth quarter of 2007. Revenues for the full year